Skip to main content
NASDAQ:CASI

CASI Pharmaceuticals Stock Forecast, Price & News

$1.39
-0.06 (-4.14 %)
(As of 05/13/2021 02:08 PM ET)
Add
Compare
Today's Range
$1.34
$1.50
50-Day Range
$1.43
$2.40
52-Week Range
$1.32
$3.90
Volume66,488 shs
Average Volume1.45 million shs
Market Capitalization$194.32 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41
30 days | 90 days | 365 days | Advanced Chart
Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


CASI Pharmaceuticals logo

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase 1/2a trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome, as well as solid tumors and lymphomas. In addition, the company offers CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors; ZEVALIN to treat patients with NHL; and MARQIBO for the treatment of adult patients with Philadelphia chromosome-negative ALL. It has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. The company also has distribution agreements with China Resources Guokang Pharmaceuticals Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600
Employees144
Year FoundedN/A

Sales & Book Value

Annual Sales$4.13 million
Book Value$0.76 per share

Profitability

Net Income$-46,030,000.00
Net Margins-402.87%

Debt

Price-To-Earnings

Miscellaneous

Market Cap$194.32 million
Next Earnings Date5/13/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

358th out of 2,042 stocks

Biological Products, Except Diagnostic Industry

44th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

Is CASI Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI Pharmaceuticals stock.
View analyst ratings for CASI Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than CASI Pharmaceuticals?

Wall Street analysts have given CASI Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CASI Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for CASI Pharmaceuticals
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its quarterly earnings results on Monday, March, 29th. The biotechnology company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.05. CASI Pharmaceuticals had a negative net margin of 402.87% and a negative trailing twelve-month return on equity of 60.96%.
View CASI Pharmaceuticals' earnings history
.

How has CASI Pharmaceuticals' stock been impacted by Coronavirus?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CASI shares have decreased by 13.5% and is now trading at $1.41.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CASI?

2 analysts have issued 12-month target prices for CASI Pharmaceuticals' stock. Their forecasts range from $3.80 to $5.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $4.40 in the next year. This suggests a possible upside of 212.1% from the stock's current price.
View analysts' price targets for CASI Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 56, Pay $810.83k)
  • Dr. Wei Zhang Ph.D., Pres (Age 62, Pay $506.1k)
  • Dr. Alexander A. Zukiwski, Chief Medical Officer (Age 64, Pay $535.35k)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 51)
  • Dr. James E. Goldschmidt, Sr. VP of Bus. Devel.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), The Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (7.26%), BlackRock Inc. (2.87%), Wellington Shields Capital Management LLC (1.60%), Wellington Shields & Co. LLC (1.31%), Geode Capital Management LLC (0.78%) and Northern Trust Corp (0.59%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, Larry Zhang, Weihao Xu and Wei-Wu He.
View institutional ownership trends for CASI Pharmaceuticals
.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, GSA Capital Partners LLP, and JPMorgan Chase & Co..
View insider buying and selling activity for CASI Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Wellington Shields Capital Management LLC, Geode Capital Management LLC, Panagora Asset Management Inc., 1492 Capital Management LLC, FNY Investment Advisers LLC, and Creative Planning. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, Larry Zhang, Weihao Xu, and Wei-Wu He.
View insider buying and selling activity for CASI Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $1.41.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals has a market capitalization of $197.11 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

CASI Pharmaceuticals employs 144 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

Where are CASI Pharmaceuticals' headquarters?

CASI Pharmaceuticals is headquartered at 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.